Biologic agents that block the effects of pro-inflammatory cytokines such as tumor necrosis factor (TNF) and IL-6 are used for the treatment of RA when disease activity can not be controlled with conventional DMARDs including MTX and substantially improve outcomes of RA [1, 2]. Here, TNF is linked to rheumatoid arthritis.